Literature DB >> 23479035

PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.

J Lee Villano1, Patrick Y Wen, Eudocia Q Lee, Lakshmi Nayak, David A Reardon, Myrna R Rosenfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23479035     DOI： 10.1007/s11060-013-1100-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  20 in total

1.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M Deangelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2012-05-31       Impact factor: 12.300

2.  Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.

Authors:  Meihua Wang; Gregory Cairncross; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

3.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

4.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Authors:  Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

5.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  Survey of treatment recommendations for anaplastic oligodendroglioma.

Authors:  Lauren E Abrey; David N Louis; Nina Paleologos; Andrew B Lassman; Jeffrey J Raizer; Warren Mason; Jonathan Finlay; David R MacDonald; Lisa M DeAngelis; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2007-04-13       Impact factor: 12.300

7.  Penetration of intra-arterially administered vincristine in experimental brain tumor.

Authors:  Frances M Boyle; Susan L Eller; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

8.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

Authors:  Murielle E L Mauer; Martin J B Taphoorn; Andrew Bottomley; Corneel Coens; Fabio Efficace; Marc Sanson; Alba A Brandes; Carin C D van der Rijt; Hans J J A Bernsen; Marc Frénay; Cees C Tijssen; Denis Lacombe; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

10.  Successful chemotherapy for recurrent malignant oligodendroglioma.

Authors:  J G Cairncross; D R Macdonald
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422
View more
  2 in total

1.  Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.

Authors:  Michael A Vogelbaum; Chen Hu; David M Peereboom; David R Macdonald; Caterina Giannini; John H Suh; Robert B Jenkins; Nadia N Laack; David G Brachman; Dennis C Shrieve; Luis Souhami; Minesh P Mehta
Journal:  J Neurooncol       Date:  2015-06-19       Impact factor: 4.130

Review 2.  Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016.

Authors:  Hikaru Sasaki; Kazunari Yoshida
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-08-25       Impact factor: 1.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.